Patents Assigned to Sapporo Medical University
  • Publication number: 20200345781
    Abstract: The present invention relates to a cell-based medicine comprising mesenchymal stem cells, and a method for producing the same. More specifically, the present invention relates to: a cell-based medicine containing mesenchymal stem cells, wherein a) the mesenchymal stem cells express CX3CL1 under stimulation with an inflammatory cytokine, and/or b) 90% or more of the mesenchymal stem cells express EGFR and/or ITGA4; and a method for producing a cell-based medicine containing mesenchymal stem cells, the method comprising the steps of: a) adding an inflammatory cytokine to a culture containing mesenchymal stem cells, and confirming that the mesenchymal stem cells express CX3CL1; and/or b) confirming that 90% or more of the mesenchymal stem cells express EGFR and/or ITGA4.
    Type: Application
    Filed: November 9, 2018
    Publication date: November 5, 2020
    Applicants: Sapporo Medical University, Nipro Corporation
    Inventors: Osamu HONMOU, Yoshihiro YOSHIKAWA, Ryo TOMII, Masafumi YAO, Yukari NISHII, Yusuke WAGATSUMA
  • Publication number: 20200341008
    Abstract: Disclosed is a method for measuring a biomarker in a biological sample of the IPAF patient, wherein the biomarker comprises at least one selected from the group consisting of CXCL9 and CXCL10, and a measurement result of the biomarker is used as an index for determining treatment responsiveness to anti-inflammatory therapy.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 29, 2020
    Applicants: SAPPORO MEDICAL UNIVERSITY, SYSMEX CORPORATION
    Inventors: Masami Kameda, Mitsuo Otsuka, Takehiro Hasegawa
  • Patent number: 10765729
    Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 8, 2020
    Assignees: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Noriyuki Sato, Toshihiko Torigoe, Yoshihiko Hirohashi, Takayuki Kanaseki, Sho Miyamoto, Vitaly Kochin, Masashi Goto
  • Publication number: 20200131470
    Abstract: [Problem] To provide a cell preparation including mesenchymal stem cells (MSCs) having a high therapeutic effect. [Solution] A method for producing activated mesenchymal stem cells, including a step of culturing MSCs in a medium containing an activator that includes an extract from a mammalian fetal appendage as an active ingredient, using a cell culture carrier having a three-dimensional structure formed of a fiber is provided. A marker for a therapeutic effect of MSCs selected from the group consisting of p16ink4a, p14ARF, CDK4, CDK6, RB, and CD47, a method for determining a therapeutic effect using the maker, a method for determining suitability of MSCs to be treated with a treatment for enhancing a therapeutic effect of MSCs, a cell preparation including MSCs, and a method for producing the same are also provided.
    Type: Application
    Filed: April 25, 2018
    Publication date: April 30, 2020
    Applicant: Sapporo Medical University
    Inventors: Takako CHIKENJI, Mineko FUJIMIYA, Yuki SAITO, Masako NAKANO, Miho OTANI, Yuka MIZUE, Takashi MATSUMURA, Kozue KAMIYA
  • Patent number: 10512660
    Abstract: [Problem] To activate an abnormal mesenchymal stem cell whose therapeutic effect is lost or reduced, or rather which has a disease-exacerbating effect so as to be in a state suitable for cell transplant therapy. [Solution] An activator for mesenchymal stem cells, mesenchymal stem cells activated by the activator, a method for producing the same, and a pharmaceutical containing the activated mesenchymal stem cells are provided.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: December 24, 2019
    Assignee: Sapporo Medical University
    Inventors: Mineko Fujimiya, Kanna Nagaishi, Yuka Mizue, Takako Chikenji
  • Publication number: 20190255118
    Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 22, 2019
    Applicant: Sapporo Medical University
    Inventor: Osamu Honmou
  • Patent number: 10376161
    Abstract: [Problem] To provide a finger arterial dilatability testing method, finger arterial dilatability testing device, and finger arterial dilatability testing program with which it is possible to simply test for early signs of arteriosclerosis using the small vessels of the finger arteries.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: August 13, 2019
    Assignee: SAPPORO MEDICAL UNIVERSITY
    Inventor: Gohichi Tanaka
  • Publication number: 20190227067
    Abstract: [Problem] The present invention addresses the problem of providing a novel biomarker which makes it possible to find the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability of glioma cells and the like and also makes it possible to detect the prognosis, the risk, the invasion ability or the like in an earlier stage of a therapy of glioma. [Solution] The present invention relates to a method for evaluating the prognosis of glioma, said method comprising the steps of: detecting ACTC1 protein and/or mRNA encoding the protein in a glioma-containing sample collected from a patient; and determining that the prognosis of the glioma is poor when the ACTC1 protein and/or the mRNA encoding the protein is detected in the aforementioned step. According to the present invention, the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability and the like can be evaluated using a novel biomarker, i.e., ACTC1 protein and/or mRNA encoding the protein.
    Type: Application
    Filed: July 28, 2016
    Publication date: July 25, 2019
    Applicant: SAPPORO MEDICAL UNIVERSITY
    Inventors: Osamu HONMOU, Masahiko WANIBUCHI, Shunya OHTAKI, Masanori SASAKI, Yuko SASAKI, Nobuhiro MIKUNI
  • Patent number: 10328102
    Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 25, 2019
    Assignee: SAPPORO MEDICAL UNIVERSITY
    Inventor: Osamu Honmou
  • Publication number: 20190183937
    Abstract: The present invention relates to a life extension agent containing CD24-negative mesenchymal stem cells and the treatment of dementia, cerebral infarction, spinal cord injury and the like using the life extension agent.
    Type: Application
    Filed: April 13, 2017
    Publication date: June 20, 2019
    Applicants: Sapporo Medical University, Nipro Corporation
    Inventors: Osamu Honmou, Masanori Sasaki, Yuko Sasaki, Rie Maezawa, Shinichi Oka, Masahito Nakazaki
  • Publication number: 20190144559
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Application
    Filed: January 24, 2019
    Publication date: May 16, 2019
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Publication number: 20190117700
    Abstract: The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.
    Type: Application
    Filed: April 26, 2017
    Publication date: April 25, 2019
    Applicants: Sapporo Medical University, Nipro Corporation
    Inventors: Osamu Honmou, Masanori SASAKI, Rie MAEZAWA, Shinichi OKA, Yuko SASAKI, Masahito NAKAZAKI, Toshihiko YAMASHITA
  • Publication number: 20190117751
    Abstract: The object of the present invention is to provide a detecting agent for specifically detecting a tumor cell, a tumor antigen peptide-specifically presented on a tumor cell, a pharmaceutical composition useful for the prevention and/or treatment of cancer, the pharmaceutical composition containing the tumor antigen peptide as an active ingredient, etc. The above object has been achieved by a tumor antigen peptide or its motif-substituted product, the tumor antigen peptide comprising 8 to 14 consecutive amino acids in an amino acid sequence of a protein encoded by a gene selected from the group consisting of PVT1, SUV39H2, ZNF724P, SNRNP40, and DYRK4, the tumor antigen peptide having an HLA binding ability.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 25, 2019
    Applicant: Sapporo Medical University
    Inventors: Toshihiko Torigoe, Takayuki Kanaseki, Vitaly Kochin, Yasuhiro Kikuchi
  • Patent number: 10227417
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 12, 2019
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Publication number: 20190054141
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Application
    Filed: August 23, 2018
    Publication date: February 21, 2019
    Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Publication number: 20190002833
    Abstract: Provided is new means for reducing risk of cerebral hemorrhage associated with a reperfusion therapy for vessel occlusion (for example, administration of a medicament including a thrombolytic agent, a platelet aggregation inhibitor, and an anticoagulant agent, or physical removal of a blood clot) and treating an ischemic vascular disorder more effectively. The present invention relates to a medicament for treating an ischemic vascular disorder, comprising mesenchymal stem cells, wherein the medicament is used in combination with a reperfusion therapy for vessel occlusion and more specifically, to a medicament for treating an ischemic vascular disorder, wherein the medicament reduces risk of cerebral hemorrhage associated with the reperfusion therapy for vessel occlusion and extends a time window in which the therapy is applicable.
    Type: Application
    Filed: December 26, 2016
    Publication date: January 3, 2019
    Applicants: Sapporo Medical University, Nipro Corporation
    Inventors: Osamu Honmou, Masahito Nakazaki, Masanori Sasaki, Yuko Sasaki, Shinichi Oka
  • Patent number: 10080776
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: September 25, 2018
    Assignees: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Publication number: 20180147270
    Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.
    Type: Application
    Filed: December 8, 2015
    Publication date: May 31, 2018
    Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Noriyuki Sato, Toshihiko Torigoe, Yoshihiko Hirohashi, Takayuki Kanaseki, Sho Miyamoto, Vitaly Kochin, Masashi Goto
  • Publication number: 20180094073
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 5, 2018
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori AGATSUMA, Shu TAKAHASHI, Jun HASEGAWA, Daisuke OKAJIMA, Hirofumi HAMADA, Miki YAMAGUCHI
  • Patent number: D836210
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: December 18, 2018
    Assignees: NIPRO CORPORATION, SAPPORO MEDICAL UNIVERSITY
    Inventors: Osamu Honmou, Tomohiro Uchimura, Kei Matsuo, Yoshihiro Yoshikawa, Yoshihito Yamagata, Masayuki Ishigami